Nutriband Stock Price, News & Analysis

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that its CEO Gareth Sheridan and President Serguei Melnik, accompanied by board members and senior management, will ring the NASDAQ Opening Bell on December 3, 2021, at 9:30 a.m. EST. Sheridan expressed gratitude for the teamwork and support that enabled the company’s journey so far. Nutriband focuses on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA™ technology. A live stream of the ceremony will be available online.

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has launched the development of its lead product, AVERSA™ Fentanyl, aiming to create the world’s first abuse-deterrent fentanyl transdermal system. This initiative follows the company's uplisting to NASDAQ and new financing. The focus will include developing a commercial strategy, market assessment, and selecting a manufacturer to expedite market entry. CEO Gareth Sheridan emphasized the importance of improving safety while ensuring accessibility for patients. Nutriband specializes in transdermal pharmaceutical products.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that an interview with CEO Gareth Sheridan will air on The RedChip Money Report on Bloomberg TV on November 13 at 7 p.m. ET. The program reaches approximately 73 million homes in the U.S. RedChip has 30 years of experience in small-cap investing commentary and interviews with public company executives.

Nutriband is focused on developing transdermal pharmaceutical products, including its lead product, an abuse deterrent fentanyl patch utilizing AVERSA® technology.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the receipt of $2,062,500 from the exercise of 275,000 warrants at $7.50 each, linked to its earlier public offering on October 1, 2021. This adds to the $6,600,000 garnered from the sale of 1,056,000 shares, bringing the total gross proceeds to approximately $8,662,500 as of October 21, 2021. Nutriband focuses on developing transdermal pharmaceutical products, particularly an abuse deterrent fentanyl patch utilizing its AVERSA technology.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has entered an exclusive manufacturing agreement with Diomics for its Diocheck™ technology, aimed at monitoring COVID-19 antibody levels. This transdermal patch provides results within 24 to 36 hours and remains effective for up to 14 days. The device is intended for assessing the effectiveness of COVID-19 vaccines over time, helping identify when boosters may be needed. The partnership showcases Nutriband's capabilities in innovative patch technologies, bolstering its position in the pharmaceutical market.

Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced an underwritten public offering of 1,056,000 units priced at $6.25 per unit, generating gross proceeds of $6.6 million. Each unit consists of one share of common stock and one warrant. The warrants are exercisable at $7.50 and expire in five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. This uplisting to the Nasdaq Capital Market aims to enhance visibility and support the company's strategic growth initiatives in developing transdermal pharmaceutical products.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that it received a Notice of Allowance from the USPTO for patent application 16/707,547, focusing on its AVERSA® technology. This technology targets the prevention of opioid abuse, particularly for fentanyl patches. The announcement follows the company's initial NASDAQ listing and a $6.6 million underwritten offering on October 1, 2021. The proceeds will primarily fund the clinical development of AVERSA.

Nutriband Inc. (NASDAQ: NTRB, NTRBW) announced its common stock and warrants began trading on the Nasdaq Capital Market on October 1, 2021. The company also priced an underwritten public offering of 1,056,000 units at $6.25 per unit, aiming for total gross proceeds of $6.6 million. Each unit comprises one share of common stock and one warrant, entitling the holder to purchase additional stock at an exercise price of $7.50. A 45-day option allows underwriters to purchase up to 158,400 additional shares to cover over-allotments. CEO Gareth Sheridan noted that this uplisting is a significant milestone for corporate visibility.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the pricing of an underwritten public offering of 1,056,000 units at $6.25 per unit, totaling gross proceeds of $6.6 million. This offering will fund the development of its abuse deterrent fentanyl patch incorporating AVERSA technology. Additionally, Nutriband's securities will commence trading on the Nasdaq Capital Market as of October 1, 2021. The company has granted underwriters a 45-day option to purchase additional shares and warrants to cover over-allotments. CEO Gareth Sheridan emphasized the uplisting's potential to enhance corporate visibility.